Center for Health Security, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Center for Communicable Disease Dynamics, Departments of Epidemiology and Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
mSphere. 2020 Jan 22;5(1):e00990-19. doi: 10.1128/mSphere.00990-19.
We propose here changes to the U.S. government policy on potential pandemic pathogen (PPP) oversight and implementation, emphasizing transparency of the review process and the content of the review, publication of the review in advance, responsible publication of enhanced PPP research, high-level signoff on approvals of enhanced PPP experiments, and the need for a significant effort to establish a common international approach to enhanced PPP work. We advocate that the U.S. government recommend, and non-U.S. government funders and journals adopt, a set of best practices that would extend important considerations of biosafety and biosecurity to all work on enhanced potential pandemic pathogens regardless of funding source.
我们在这里提议对美国政府关于潜在大流行病原体（PPP）监督和实施的政策进行修改，强调审查过程和审查内容的透明度，提前公布审查结果，负责任地公布增强型 PPP 研究成果，对增强型 PPP 实验的批准进行高级别签字，并需要做出重大努力建立增强型 PPP 工作的共同国际方法。我们主张美国政府建议，并且非美国政府的资助者和期刊采用一套最佳实践，将生物安全和生物安保的重要考虑因素扩展到所有增强型潜在大流行病原体的工作，无论资金来源如何。
